CA
GTBP icon

Crumly & Associates’s GT Biopharma GTBP Stock Holding History

Crumly & Associates’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,072
Closed -$96K – 107
2022
Q2 		$96K Hold
1,072
– – 0.04% 105
2022
Q1 		$93K Hold
1,072
– – 0.03% 108
2021
Q4 		$85K Buy
+1,072
New +$160K 0.03% 103

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Crumly & Associates's GTBP Position: Q3 2022 in Review

Crumly & Associates sold out of GT Biopharma (GTBP) in Q3 2022, closing a stake of 1,072 shares — an estimated $96K sold.

Crumly & Associates first reported a position in GTBP in Q4 2021 and held it in 3 quarters. The position peaked at $96K in Q2 2022. 34 funds tracked by Wall St. Rank hold GTBP as of Q3 2022.

  • Crumly & Associates reported no remaining GT Biopharma position as of Q3 2022 after selling out during the quarter.
  • Crumly & Associates sold 1,072 GT Biopharma shares in Q3 2022, an estimated $96K.
  • Crumly & Associates first reported a position in GT Biopharma in Q4 2021 and held it in 3 quarters.
  • Crumly & Associates's GT Biopharma position peaked at $96K in Q2 2022.
  • 34 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2022.

Based on Crumly & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.